ClearOne to Merge with Vivani Medical's Cortigent, Pivoting to Medical Devices with $10M-$15M Financing
CLRO sits 19% above its 52-week low of $2.71.
Summary
ClearOne, facing delisting and a going concern warning, announced a transformative merger with Cortigent, a Vivani Medical subsidiary. The deal pivots ClearOne into the medical device sector, focusing on neurostimulation, and includes a planned $10M-$15M financing. Vivani will own 59.4% to 67.5% of the combined entity, which will be renamed Cortigent Holdings, Inc. This strategic shift provides a critical lifeline and new business direction for the distressed company, following its recent divestiture of its prior operations and small capital raises. The transaction is expected to close in Q3 2026, pending stockholder approvals and financing.
At the time of this announcement, CLRO was trading at $3.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.6M. The 52-week trading range was $2.71 to $15.42. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.